<DOC>
	<DOC>NCT00152490</DOC>
	<brief_summary>A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease</brief_summary>
	<brief_title>A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)</brief_title>
	<detailed_description>Receiving immunosuppressants (azathioprine/6-MP/methotrexate) at Week 0 or not. 604 patients will be enrolled with 1006 patients screened (to allow for 25% screen failures between screening and Week 0 and expected presentation at Screening of 60% of patients with CRP &lt; 10 mg/L and 40% of patients with CRP ≥ 10 mg/L).</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Definitive diagnosis of Crohn's disease confirmed (at least 3 months prior to study entry) either by radiological, endoscopic or histological evidence, affecting the terminal ileum (L1), colon (L2) or ileocolon (L3*. *Vienna Classification (1998) Active Crohn's disease (≥ 220 and ≤ 450) scored over the 7 days prior to the first dose of study drug. Male and female aged 18 years or above at screening. Patients who meet all concomitant medication criteria in the protocol specified table. For all drugs being taken at screening, the patient should be able to remain on a stable dose throughout the duration of the study, although steroids may be tapered starting at Weeks 8 to 12. Crohn's Disease Related Fistula abscess present at screening. Stricturing type disease with symptoms or signs of noninflammatory mechanical obstruction or bowel perforation in last 3 months. Short bowel syndrome. Functional colostomy or ileostomy (note: patients who have had a temporary stoma in the past, which has been reversed, are eligible to enter the study). Positive stool laboratory results for enteric pathogens.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Crohn's disease, CDP870, CDAI, clinical response, remission,</keyword>
	<keyword>Certolizumab Pegol, Cimzia</keyword>
</DOC>